Withdrawal Signs Occurred Without Matching ERK-Pathway Changes in a Rat Study
Observable cannabinoid withdrawal did not require a detectable change in every measured signaling marker. A rat experiment reported withdrawal signs without concurrent changes in selected Raf-MEK-ERK phosphorylation measurements.
The study tracked several treatment phases
Researchers measured frontal-cortex signaling after acute WIN55,212-2, repeated exposure and antagonist administration after chronic treatment. They also examined temperature and used pathway inhibitors to investigate the signaling sequence.
Acute activation adapted with repetition
The abstract reports acute increases in phosphorylated pathway components, reduced signaling activation after repeated treatment and tolerance to the temperature effect. Rimonabant after chronic treatment elicited the expected withdrawal syndrome.
The withdrawal marker comparison was negative
Despite the behavioral syndrome, the measured phosphorylation state of the listed pathway proteins did not change concurrently. That result limits using those measurements as a universal readout of withdrawal.
A negative marker does not erase an observed behavioral effect, just as a positive marker would not by itself establish a clinical syndrome. These were rat cortical measurements with an experimental agonist and precipitating antagonist. They do not validate a human laboratory test for cannabis withdrawal or identify whether a particular person was impaired. The study separates treatment-phase biology from a single global biomarker claim.
Related: interpreting cannabis tolerance claims.
Research cited
Moranta D; Esteban S; García-Sevilla JA. Acute, chronic and withdrawal effects of the cannabinoid receptor agonist WIN55212-2 on the sequential activation of MAPK/Raf-MEK-ERK signaling in the rat cerebral frontal cortex: short-term regulation by intrinsic and extrinsic pathways. Journal of neuroscience research (2007). doi:10.1002/jnr.21140. Findings discussed from the study abstract.
